arrow
Y

Yiheng Chen

Merck & Co. Inc.
H指数:18
被引数:2,251

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery Process of Enlicitide; a Highly Engineered Macrocyclic Peptide Therapeutic; through Issue-Driven Fragment-Based Synthetic Assembly and SAR

通过问题驱动的片段基础合成组装和构效关系研究发现的恩利西肽;一种高度工程化的大环肽治疗药物

2026-05-270
PRE
A genetic variant associated with aquaporin 3 expression is correlated to in-hospital death in COVID-19 patients with extracellular hyperosmolality

与水通道蛋白3表达相关的遗传变异与外渗高渗性COVID-19患者的院内死亡相关。

2025-06-010
PRE
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors
2024-09-040
PRE
Integrating genetics and metabolomics from multi- ethnic and multi-fluid data reveals putative mechanisms for age-related macular degeneration

整合来自多种族和多流体数据的遗传学和代谢组学揭示了年龄相关性黄斑变性的推定机制

2023-07-0114
OAAI
Circulating proteins to predict COVID-19 severity

循环蛋白质预测新型冠状病毒肺炎严重程度

2023-04-177
OAAI
Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity
2023-02-2027
OAAI
Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases

血浆代谢组的基因组图谱优先考虑与人类疾病有关的代谢物

2023-01-12241
OA
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity
2021-02-25164
OAAI